Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group

[1]  J. Byrd,et al.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. , 2019, Blood.

[2]  K. Yoo,et al.  Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) , 2019, Bone Marrow Transplantation.

[3]  W. Faridi,et al.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  J. Sosman,et al.  Immune Checkpoint Inhibitor Toxicity in 2018 , 2018, JAMA.

[5]  M. Pasquini,et al.  Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  M. Carlino,et al.  Immune Checkpoint Inhibitor Toxicity , 2018, Current Oncology Reports.

[7]  A. Vekhoff,et al.  Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  P. Richardson,et al.  Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome , 2018, British journal of haematology.

[9]  A. Seif,et al.  The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant , 2018, Bone Marrow Transplantation.

[10]  D. Nilsson,et al.  Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites , 2017, Pediatric blood & cancer.

[11]  P. Hari,et al.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. , 2017, Blood.

[12]  P. Richardson,et al.  Earlier defibrotide initiation post‐diagnosis of veno‐occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation , 2017, British journal of haematology.

[13]  Shannon R. McCurdy,et al.  Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Houot,et al.  Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. , 2017, Blood.

[15]  R. Houot,et al.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. , 2017, Blood.

[16]  K. Myers,et al.  Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  P. Richardson,et al.  Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[19]  M. Abecassis,et al.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.

[20]  R. D'Agostino,et al.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.

[21]  S. Giralt,et al.  Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  T. Miyamoto,et al.  Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes , 2016, Bone Marrow Transplantation.

[23]  M. Abecassis,et al.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.

[24]  E. Carreras.  How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation , 2015, British journal of haematology.

[25]  M. Díaz-Ricart,et al.  Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  K. Myers,et al.  High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  H. Eom,et al.  Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation. , 2013, Annals of transplantation.

[28]  P. Richardson,et al.  Drug safety evaluation of defibrotide , 2013, Expert opinion on drug safety.

[29]  A. Schulz,et al.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.

[30]  M. Díaz-Ricart,et al.  Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.

[31]  Allen R. Chen,et al.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  Allen R. Chen,et al.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  M. Aljurf,et al.  Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone , 2008, Bone Marrow Transplantation.

[34]  M. Terol,et al.  Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  G. Morgan,et al.  Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease , 2007, Bone Marrow Transplantation.

[36]  D. Allan,et al.  Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  H. Im,et al.  Prophylactic Low-dose Heparin or Prostaglandin E1 may Prevent Severe Veno-occlusive Disease of the Liver after Allogeneic Hematopoietic Stem Cell Transplantation in Korean Children , 2006, Journal of Korean medical science.

[38]  M. Artesani.  Anaphylactic shock to defibrotide , 2006, Allergy.

[39]  I. Tleyjeh,et al.  Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis , 2006, Bone Marrow Transplantation.

[40]  B. Chapuis,et al.  Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  Allen R. Chen,et al.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.

[42]  M. Remberger,et al.  Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.

[43]  S. Uemoto,et al.  A Successful Liver Transplantation for Refractory Hepatic Veno‐Occlusive Disease Originating from Cord Blood Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  Ha Yeon Lee,et al.  A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[45]  K. Ohashi,et al.  The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno‐occlusive disease after stem cell transplantation , 2000, American journal of hematology.

[46]  H. Bismuth,et al.  Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation , 2000, Bone Marrow Transplantation.

[47]  Jung Lim Lee,et al.  Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  D. Neuberg,et al.  Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.

[49]  N. Callander,et al.  Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation , 1998, Annals of Internal Medicine.

[50]  F. Appelbaum,et al.  A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation , 1993 .

[51]  D. Shen,et al.  A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation , 1993, British journal of haematology.

[52]  G. Laurent,et al.  Prevention of Regimen-Related Toxicities After Bone Marrow Transplantation by Pentoxifylline: A Prospective, Randomized Trial , 1993 .

[53]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[54]  A. Grañena,et al.  On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease , 1993, Annals of Hematology.

[55]  P. Bordigoni,et al.  PROSTAGLANDIN E1 (PGE1) INDUCED ARTHRITIS FOLLOWING BONE MARROW TRANSPLANTATION , 1991, British journal of haematology.

[56]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[57]  Libo Zhao,et al.  Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis. , 2019, Critical reviews in oncology/hematology.

[58]  M. Remberger,et al.  Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[59]  J. Fischer,et al.  Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. , 2006, Haematologica.

[60]  Pankaj Sharma,et al.  Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.